209 related articles for article (PubMed ID: 25821319)
1. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.
Balkan II; Batirel A; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
Indian J Pharmacol; 2015; 47(1):95-100. PubMed ID: 25821319
[TBL] [Abstract][Full Text] [Related]
2. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
[TBL] [Abstract][Full Text] [Related]
3. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections.
Lim SK; Lee SO; Choi SH; Choi JP; Kim SH; Jeong JY; Choi SH; Woo JH; Kim YS
J Korean Med Sci; 2011 Mar; 26(3):325-31. PubMed ID: 21394298
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Oliva A; Liguori L; Covino S; Petrucci F; Cogliati-Dezza F; Curtolo A; Savelloni G; Comi M; Sacco F; Ceccarelli G; Viscido A; Alessandri F; Raponi G; Pugliese F; Mastroianni CM; Venditti M
Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1149-1160. PubMed ID: 38634975
[TBL] [Abstract][Full Text] [Related]
5. Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment.
Lee YT; Sun JR; Wang YC; Chiu CH; Kuo SC; Chen TL; ; Yang YS
Int J Antimicrob Agents; 2020 Jun; 55(6):105956. PubMed ID: 32278810
[TBL] [Abstract][Full Text] [Related]
6. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
[TBL] [Abstract][Full Text] [Related]
7. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.
Poulikakos P; Tansarli GS; Falagas ME
Eur J Clin Microbiol Infect Dis; 2014 Oct; 33(10):1675-85. PubMed ID: 24832022
[TBL] [Abstract][Full Text] [Related]
8. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study.
Russo A; Bassetti M; Ceccarelli G; Carannante N; Losito AR; Bartoletti M; Corcione S; Granata G; Santoro A; Giacobbe DR; Peghin M; Vena A; Amadori F; Segala FV; Giannella M; Di Caprio G; Menichetti F; Del Bono V; Mussini C; Petrosillo N; De Rosa FG; Viale P; Tumbarello M; Tascini C; Viscoli C; Venditti M;
J Infect; 2019 Aug; 79(2):130-138. PubMed ID: 31145911
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Acute Kidney Injury and 28-Day Mortality in Carbapenem-Resistant
Yu SN; Kim T; Park SY; Lee YM; Park KH; Lee EJ; Jeon MH; Choo EJ; Kim TH; Lee MS; Park SY
Microb Drug Resist; 2021 Aug; 27(8):1029-1036. PubMed ID: 33656377
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
Kengkla K; Kongpakwattana K; Saokaew S; Apisarnthanarak A; Chaiyakunapruk N
J Antimicrob Chemother; 2018 Jan; 73(1):22-32. PubMed ID: 29069421
[TBL] [Abstract][Full Text] [Related]
11. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.
Lan M; Dongmei K; Guodong S; Haifeng Y; Guofeng C; Mengting C; Xiaoyun F
BMC Infect Dis; 2024 Apr; 24(1):448. PubMed ID: 38671347
[TBL] [Abstract][Full Text] [Related]
14. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
Kalin G; Alp E; Akin A; Coskun R; Doganay M
Infection; 2014 Feb; 42(1):37-42. PubMed ID: 23828559
[TBL] [Abstract][Full Text] [Related]
15. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
Durante-Mangoni E; Signoriello G; Andini R; Mattei A; De Cristoforo M; Murino P; Bassetti M; Malacarne P; Petrosillo N; Galdieri N; Mocavero P; Corcione A; Viscoli C; Zarrilli R; Gallo C; Utili R
Clin Infect Dis; 2013 Aug; 57(3):349-58. PubMed ID: 23616495
[TBL] [Abstract][Full Text] [Related]
16. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital.
Li KL; Abad CLR
Int J Infect Dis; 2020 Apr; 93():9-14. PubMed ID: 31978579
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and appropriateness of management of nosocomial Acinetobacter bloodstream infections at a teaching hospital in northeastern Malaysia.
Deris ZZ; Harun A; Shafei MN; Rahman RA; Johari MR
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):140-7. PubMed ID: 19323046
[TBL] [Abstract][Full Text] [Related]
19. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Zheng JY; Huang SS; Huang SH; Ye JJ
J Microbiol Immunol Infect; 2020 Dec; 53(6):854-865. PubMed ID: 31607573
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure.
Wang YC; Lee YT; Yang YS; Chen CT; Chiu CH; Yin T; Kuo SC; Chen TL; Lin JC; Wang FD; Fung CP; Chang FY
Clin Microbiol Infect; 2015 Aug; 21(8):758-64. PubMed ID: 25980356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
